Viva Biotech Holdings disclosed that, as of 29 May 2026, the company has repurchased a total of 19.94 million ordinary shares under the buy-back mandate approved on 12 June 2025. The repurchased shares equal 0.94 % of the issued share capital outstanding on the mandate date. No shares have yet been cancelled, so the issued share count remains unchanged at 2.13 billion.

On 29 May 2026, the most recent trading day covered by the filing, Viva Biotech bought back 820,500 shares on the Hong Kong Stock Exchange at prices ranging between HKD 1.23 and HKD 1.26, for an aggregate consideration of HKD 1.02 million. These shares are intended for cancellation, and a moratorium on new share issues is in effect until 28 June 2026.

Since the start of the current month, the company has executed 15 on-market repurchases, with daily volumes ranging from 493,500 to 4.16 million shares and volume-weighted average prices between HKD 1.25 and HKD 1.57. The mandate allows the company to repurchase up to 212.84 million shares, leaving 192.90 million shares, or 90.58 % of the authorisation, still available.

Apart from the buy-backs, the filing confirms there were no new share issues, transfers of treasury shares or changes in the total number of issued shares during the reporting period. All repurchases were conducted in compliance with Hong Kong Listing Rules and the terms of the shareholder-approved mandate.